Wageningen University
Wageningen, 6703 HD, Netherlands
NCT Number: NCT01694056
Soy protein has a high biological value, and contains several potential health-related nutritional factors, i.e. its amino acids pattern, biological active peptides and non-protein compounds such as isoflavones. In the field of obesity and blood lipids soy protein is well-studied and appreciated; it improves circulating blood lipids and is associated with weight reduction. The effect of soy on insulin resistance, glucose homeostasis and the metabolic syndrome is less frequently studied. However, several molecular mechanisms of action of soy protein make it a promising approach.
Looking for future studies?
Notify Me45 year–70 year
Female
Interventional
Not applicable
Wageningen, 6703 HD, Netherlands
Objective: The primary objective of the present study is to evaluate the effect of a high soy protein diet on insulin resistance and glycemic control in participants with characteristics of the metabolic syndrome. Secondly, the present study will evaluate whether reduced low-grade inflammation is a possible mechanism underlying the improvement in insulin resistance and glucose homeostasis. Finally, it will be assessed whether soy protein has beneficial effects on components of the metabolic syndrome, such as cardio-metabolic risk factors, blood lipid profile, blood pressure and endothelial function, fat storage in the liver and gene-expression in subcutaneous abdominal adipose tissue.
Study design: Single-blind, cross-over strictly-controlled dietary intervention.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Plus any one of the following four factors:
Exclusion criteria
4 weeks high protein diet (20 en%) with 25gr of soy protein per day
4 weeks high mixed protein diet (20 en%)
Time frame: 4 weeks
Insulin sensitivity is measured with an intravenous glucose tolerance test (IVGTT).
Time frame: 4 weeks
Adipose tissue samples will be collected for subsequent gene expression analysis.
Time frame: 4 weeks
Circulating triglycerides, free fatty acids (FFA), and HDL and total cholesterol will be measured in fasted blood samples, LDL will be calculated.
Time frame: 4 weeks
For low-grade inflammation interleukins, tumor necrosis factor-α, C-reactive protein and adipokines will be measured in fasting blood samples. Furthermore, peripheral blood mononuclear cells (PBMC's) will be collected to measure expression of genes involved in lipid handling and inflammation.
Time frame: 4 weeks
Blood pressure and macro vascular regional arterial stiffness will be assessed by Pulse Wave Analysis (PWA). Besides PWA, we will also measure markers for endothelial function in fasting blood samples.
Time frame: 4 weeks
Hepatic lipid content The lipid content in liver will be quantified by proton magnetic resonance spectroscopy (1H -MRS)
Wageningen University
Other
Soy Protein Intake and the Metabolic Syndrome: Reducing Inflammation to Improve Insulin Resistance and Glucose Homeostasis
Acronym: SOY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02298725
Body Weight, Glucose Metabolism Disorders
Davis, California, United States
View Trial DetailsNCT03309761
Glucose Metabolism Disorders, Hyperinsulinism
Nîmes, France
View Trial DetailsNCT06907108
Dyssomnias, Glucose Metabolism Disorders
Rio de Janeiro, Brazil
View Trial DetailsNCT06877130
Cardiovascular Problems in Elderly, Glucose Metabolism Disorders
Giza, Giza Governorate, Egypt
View Trial Details